Explore
Trendline
CervoMed Reports $7.96M Net Loss in Q1 2026 Amid Clinical Investments
CervoMed Reports $7.96M Net Loss in Q1 2026 Amid Clinical Investments
Read More
Trendline
CervoMed Inc. Reports Zero Revenue and Increased Net Loss in Q1 2026
CervoMed Inc. Reports Zero Revenue and Increased Net Loss in Q1 2026
Read More
Trendline
Palatin Technologies Reports Q3 2026 Financial Results and Business Progress
Palatin Technologies Reports Q3 2026 Financial Results and Business Progress
Read More
Trendline
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
Read More
Trendline
INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107
INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107
Read More
Trendline
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements
NanoViricides Reports $1.99M Net Loss in Q3 FY2026 Amid Clinical Advancements
Read More
Trendline
Palatin Reports Reduced Net Loss and Advances Obesity Programs
Palatin Reports Reduced Net Loss and Advances Obesity Programs
Read More
Trendline
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Read More
Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results
Immunome Submits NDA for Varegacestat and Reports Financial Results
Read More
Trendline
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Nanoviricides Reports Third Quarter Loss Amid Clinical Advancements
Read More
Trendline
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Read More
Trendline
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Advances
Lantern Pharma to Announce Q1 2026 Financial Results, Highlighting AI-Driven Oncology Advances
Read More
